Swanhill Capital
745 Fifth Ave., Suite 500, New York, NY, 10151, United States
Overview
Swanhill Capital is an investment partnership dedicated to actively pursue investments in healthcare companies, excluding biotechnology and pharmaceutical ventures. They are committed to long-term capital appreciation and to expanding their investment portfolio. They opportunistically participate as a minority or majority investor by infusing capital in companies at all phases of their life cycle from a seed round to a traditional LBO. Swanhill Capital was founded in 2007 and is headquartered in New York.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- 1DOC3
Participated · Series A · Apr 2021
1Doc3 offers a telemedicine platform optimized for Latin America that uses text and chat (rather than video) and AI to do symptom assessment, triage and pre-diagnosis before connecting patients to doctors. The service connects patients to doctors within minutes in 97% of consultations and can arrange prescription delivery to patients' homes. The company reaches customers directly and via corporate partnerships where employers pay for employees' care, charging corporates about $3–4 per month per employee. 1Doc3 experienced rapid growth in 2020, rising from 2,500 to 35,000 consultations per month between February and December, became cashflow positive last year, and reported $120,000 in MRR in March 2021. It currently operates in Colombia and Mexico and plans to use new funding to expand further in the region and to build out a marketing and sales team. The company was founded in 2013 and was a finalist in TechCrunch’s Latin American Battlefield in 2018.
- Cohero Health
Participated · Seed · Dec 2015
Cohero Health develops connected care devices and mobile and web applications under its BreatheSmart platform to engage respiratory patients, track medication adherence, and measure lung function. Its product suite includes wireless inhaler sensors, an FDA-cleared mobile spirometer, patient-facing mobile apps with reminders and rewards, and HIPAA-compliant web access for custom data. The company is building a large dataset of respiratory patient demographics, medication utilization, symptoms, pulmonary function, outcomes and costs. Cohero has deployed its platform across more than 25 commercial partnerships, representing over 1 million pediatric and adult asthma, COPD, and cystic fibrosis patients. Led by co-founder and CEO Melissa Manice, PhD, and co-founder and COO Dan Weinstein, the company is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech. It plans to use new funding to grow commercial business development, expand its clinical trial program, and further evolve the BreatheSmart platform. Cohero Health develops connected devices and mobile applications aimed at engaging and empowering respiratory patients by measuring lung function and tracking adherence. Its proprietary platform includes wireless medication inhaler sensors, an FDA-cleared mobile spirometer, patient-facing mobile apps that generate reminders and reward compliance, and HIPAA-compliant servers for custom data access. The company is led by Melissa Manice, PhD, and is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech. Cohero closed a $2M seed funding round to support scaling and commercialization. The company plans to use the funds to scale production of its devices for large customer deployments and to support the full-scale commercial launch of its platform. No operating metrics (revenue/users) were disclosed in the sourced article.
Team
No current team members are available.